SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

11/12/24 10:34:14 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TEVA alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 TEVA PHARMACEUTICAL INDS LTD COMMON STOCK Cusip #M8769Q102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #M8769Q102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 62,301,623 Item 6: 0 Item 7: 62,740,762 Item 8: 0 Item 9: 62,740,762 Item 11: 5.537% Item 12: HC Cusip #M8769Q102 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 62,740,762 Item 8: 0 Item 9: 62,740,762 Item 11: 5.537% Item 12: IN Item 1(a). Name of Issuer: TEVA PHARMACEUTICAL INDS LTD Item 1(b). Address of Issuer's Principal Executive Offices: 5 Bazel St, POB 3190 Petach, Tikva 49131 Israel Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: M8769Q102 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 62,740,762 (b) Percent of Class: 5.537% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 62,740,762 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of TEVA PHARMACEUTICAL INDS LTD. No one other person's interest in the COMMON STOCK of TEVA PHARMACEUTICAL INDS LTD is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of TEVA PHARMACEUTICAL INDS LTD at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $TEVA alert in real time by email

Recent Analyst Ratings for

$TEVA

Date	Price Target	Rating	Analyst
6/6/2025	$24.00	Buy	Goldman
5/28/2025	$25.00	Buy	Truist
5/12/2025	$23.00	Neutral → Overweight	Analyst
7/10/2024	$20.00	Hold → Buy	Argus
3/8/2024	$14.00	Underweight → Neutral	JP Morgan
2/12/2024	$12.00 → $19.00	Neutral → Overweight	Piper Sandler
1/23/2024	$10.00 → $14.00	Hold → Buy	Jefferies
1/3/2024	$8.00 → $12.00	Underweight → Neutral	Piper Sandler

More analyst ratings

SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

11/12/24 10:34:14 AM ET

$TEVA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TEVA alert in real time by email

Recent Analyst Ratings for

$TEVA

Date	Price Target	Rating	Analyst
6/6/2025	$24.00	Buy	Goldman
5/28/2025	$25.00	Buy	Truist
5/12/2025	$23.00	Neutral → Overweight	Analyst
7/10/2024	$20.00	Hold → Buy	Argus
3/8/2024	$14.00	Underweight → Neutral	JP Morgan
2/12/2024	$12.00 → $19.00	Neutral → Overweight	Piper Sandler
1/23/2024	$10.00 → $14.00	Hold → Buy	Jefferies
1/3/2024	$8.00 → $12.00	Underweight → Neutral	Piper Sandler

More analyst ratings

SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$TEVA

SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$TEVA

$TEVA
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Teva Pharmaceutical Industries Limited

SEC Form 10-Q filed by Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$TEVA
Press Releases

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

Teva Releases Q2 2025 Aide Memoire

$TEVA
Analyst Ratings

Goldman initiated coverage on Teva Pharma with a new price target

Truist initiated coverage on Teva Pharma with a new price target

Teva Pharma upgraded by Analyst with a new price target

$TEVA
Insider Trading

See "Remarks" Jover Placid converted options into 12,827 units of Ordinary Shares and sold $91,748 worth of Ordinary Shares (6,053 units at $15.16) (SEC Form 4)

See "Remarks" Hughes Eric A converted options into 52,742 units of Ordinary Shares and sold $799,437 worth of Ordinary Shares (52,742 units at $15.16) (SEC Form 4)

EVP, Chief Financial Officer Kalif Eliyahu Sharon sold $952,464 worth of Ordinary Shares (55,775 units at $17.08), decreasing direct ownership by 12% to 403,288 units (SEC Form 4)

$TEVA
Leadership Updates

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

$TEVA
Financials

Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved

$TEVA
Large Ownership Changes